Intract pharma ltd

Intract Pharma Ltd: Revolutionizing Patient Care with Innovative Oral Therapeutics

Intract Pharma Ltd is a leading pharmaceutical company that specializes in developing innovative oral therapeutics to replace injections and other invasive methods of drug delivery. The company's mission is to transform patient care by providing safer, more effective, and more convenient treatment options for a wide range of medical conditions.

Founded in 2011, Intract Pharma has quickly established itself as a pioneer in the field of oral drug delivery. The company's proprietary technology platform, known as Phloral®, enables the targeted delivery of drugs to specific regions of the gastrointestinal tract, thereby enhancing their efficacy and reducing side effects.

Intract Pharma's team of experienced scientists and researchers are dedicated to advancing the science of oral drug delivery through cutting-edge research and development. The company has collaborated with leading academic institutions and pharmaceutical companies around the world to bring its innovative products to market.

One of Intract Pharma's most promising products is INT-767, an oral therapy for non-alcoholic steatohepatitis (NASH), a chronic liver disease that affects millions worldwide. INT-767 combines two drugs that target different aspects of NASH pathology, offering a potentially more effective treatment option than existing therapies.

Another key product in Intract Pharma's pipeline is INT-777, an oral therapy for inflammatory bowel disease (IBD), which affects over 3 million people in the US alone. INT-777 targets specific receptors in the gut that are involved in inflammation and immune response, offering a novel approach to treating IBD.

In addition to its focus on developing new therapies for unmet medical needs, Intract Pharma also offers contract research services for other pharmaceutical companies looking to develop their own oral therapeutics using Phloral® technology. This includes formulation development, preclinical testing, clinical trial design and execution support.

Overall, Intract Pharma Ltd represents an exciting opportunity for investors looking to capitalize on the growing demand for innovative oral therapeutics. With a strong pipeline of products and a proven track record of success, the company is well-positioned to transform patient care and revolutionize the pharmaceutical industry.